Kirkland Represents Bristol Myers Squibb on $4.1 Billion Acquisition of Turning Point Therapeutics
Kirkland & Ellis advised Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, on its acquisition of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis, for $4.1 billion. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022.
Read the Bristol Myers Squibb press release
The Kirkland team was led by corporate partners Jonathan Davis, Steven Li and Daniel Wolf and associate Rebecca Roach, capital markets partner Sophia Hudson, technology & IP transactions partners Lisa Samenfeld and Amber Harezlak, and IP litigation partner Patricia Carson.